Brittany Hanes
Family · Orangeburg, SCNPI 1992380554
Payments from drug & device makers
Across 194 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$822
- AbbVie$320
- Theratechnologies Inc.$187
- Merck$141
- Johnson & Johnson$120
- plus $464 from 12 others
What the payments were for
- Food & beverage$3,65297%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 87 | $1,698 |
| Gilead | 40 | $822 |
| AbbVie | 17 | $320 |
| Theratechnologies Inc. | 8 | $187 |
| Merck | 10 | $141 |
| Johnson & Johnson | 10 | $120 |
| Janssen Products, LP | 1 | $100 |
| Amgen | 5 | $82 |
| Novartis | 4 | $77 |
| Medtronic | 1 | $37 |
| Pfizer | 2 | $29 |
| GSK | 2 | $29 |
| Exact Sciences | 2 | $28 |
| Napo Pharmaceuticals Inc | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Indivior Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $4 |
How this compares
$3,752 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 408 | $1,573,215 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 137 | $492,452 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 109 | $410,390 |
| TivicayDolutegravir Sodium | 156 | $396,789 |
| PrezcobixDarunavir/Cobicistat | 106 | $250,485 |
| DovatoDolutegravir Sodium/Lamivudine | 51 | $150,493 |
| DescovyEmtricitabine/Tenofov Alafenam | 67 | $145,471 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 32 | $117,109 |
| Isentress HdRaltegravir Potassium | 48 | $92,609 |
| Darunavir | 33 | $52,059 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 11 | $48,656 |
| PrezistaDarunavir | 22 | $43,781 |
| JulucaDolutegravir/Rilpivirine | 13 | $42,920 |
| PifeltroDoravirine | 20 | $34,485 |
| IsentressRaltegravir Potassium | 13 | $25,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $822 | $2,129,076584 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Triumeq, Juluca | $1,698 | $707,311252 claims |
| Johnson & JohnsonPrezcobix | $120 | $250,485106 claims |
| MerckIsentress Hd, Pifeltro, Isentress | $141 | $152,99881 claims |
| Janssen Products, LPSymtuza | $100 | $48,65611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.
Other family in Orangeburg
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.